I only skimmed the study, but at a glance, the study seems fine, if a bit unremarkable, but the article reporting the study seems a bit confused.
1. The study doesn't study Ozempic (Semaglutide), it studies Liraglutide. Why is the article titled "Life after Ozempic"?
2. Okay, so some patients stopped taking a weight loss drug and stopped exercising, and gained weight. That's pretty much exactly what you'd expect, yet the article seems to be presenting this as if it's a problem with Liraglutide. "Medicine doesn't work when you don't take it" is a bizarre criticism.
The conclusion to the follow-up study might have a clue to (1.):
> The addition of supervised exercise to obesity pharmacotherapy seems to improve healthy weight maintenance after treatment termination compared with treatment termination of obesity pharmacotherapy alone.
Ozempic in the title could be a stand-in for "obesity pharmacotherapy" and maybe they chose the more recognizable brand name.
It's also not very surprising that those in the supervised exercise group were better off a year later, they'd developed a healthy habit.
Liraglutide is a GLP-1 very similar to semaglutide, but at this point I think Ozempic is the "Kleenex" of GLP-1s. I'd be very surprised if one GLP-1 had a particularly different post-use profile than another.
I only skimmed the study, but at a glance, the study seems fine, if a bit unremarkable, but the article reporting the study seems a bit confused.
1. The study doesn't study Ozempic (Semaglutide), it studies Liraglutide. Why is the article titled "Life after Ozempic"?
2. Okay, so some patients stopped taking a weight loss drug and stopped exercising, and gained weight. That's pretty much exactly what you'd expect, yet the article seems to be presenting this as if it's a problem with Liraglutide. "Medicine doesn't work when you don't take it" is a bizarre criticism.